Business Context and Reporting Period
This Form 8-K was filed by Leap Therapeutics, Inc. on February 1, 2019. The registrant is a Delaware corporation and an emerging growth company. The report details the entry into a material definitive agreement regarding an underwritten public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 6,571,428 shares of common stock paired with warrants to purchase an equal number of shares.
- Offering Price: $1.75 per share and accompanying warrant.
- Warrant Terms: Exercise price of $1.95 per share; exercisable immediately; expiration date of February 5, 2026.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 985,714 additional shares and/or warrants.
- Expected Net Proceeds: Approximately $10.5 million (excluding over-allotment and warrant exercise proceeds).
- Use of Proceeds: Funding clinical trials for DKN-01 and TRX518, capital expenditures, working capital, and general administrative expenses.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with Raymond James & Associates, Inc. and Ladenburg Thalmann & Co. Inc. as book-running managers. The transaction is expected to close on February 5, 2019, subject to customary conditions. Additionally, certain officers, directors, and 5% shareholders have agreed to a 60-day lock-up period, restricting the sale of their common stock without underwriter consent.
Outlook, Risks, and Contingencies
The company intends to utilize the capital raised to advance its clinical pipeline, specifically for DKN-01 and TRX518. The filing notes that the Underwriting Agreement contains customary representations, warranties, and indemnification obligations. The transaction is contingent upon the satisfaction of closing conditions and the effectiveness of the prospectus supplements filed under the company's shelf registration statement (No. 333-223419).
Investor Verification Checklist
- Verify the final closing date of the offering (expected February 5, 2019) and confirmation of net proceeds received.
- Review the final prospectus supplement for any changes to the offering price or warrant terms.
- Monitor the exercise of the underwriters' over-allotment option within the 30-day window.
- Confirm the specific allocation of funds toward the DKN-01 and TRX518 clinical trials in subsequent reports.
- Check for any updates regarding the lock-up expiration for insiders after the 60-day period.